Medical - Instruments & Supplies
Compare Stocks
3 / 10Stock Comparison
EKSO vs IRBT vs CYBR
Revenue, margins, valuation, and 5-year total return — side by side.
Furnishings, Fixtures & Appliances
Software - Infrastructure
EKSO vs IRBT vs CYBR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Furnishings, Fixtures & Appliances | Software - Infrastructure |
| Market Cap | $29M | $2M | $20.64B |
| Revenue (TTM) | $12M | $547M | $1.36B |
| Net Income (TTM) | $-16M | $-209M | $-147M |
| Gross Margin | 52.9% | 22.0% | 74.3% |
| Operating Margin | -134.1% | -29.5% | -7.7% |
| Forward P/E | — | — | 81.9x |
| Total Debt | $3M | $227M | $1.22B |
| Cash & Equiv. | $1M | $134M | $623M |
EKSO vs IRBT vs CYBR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ekso Bionics Holdin… (EKSO) | 100 | 20.5 | -79.5% |
| iRobot Corporation (IRBT) | 100 | 0.1 | -99.9% |
| CyberArk Software L… (CYBR) | 100 | 415.1 | +315.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EKSO vs IRBT vs CYBR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EKSO is the clearest fit if your priority is dividends and momentum.
- 0.8% yield; the other 2 pay no meaningful dividend
- +79.3% vs IRBT's -97.7%
IRBT plays a supporting role in this comparison — it may shine differently against other peers.
CYBR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.92
- Rev growth 36.0%, EPS growth -38.2%, 3Y rev CAGR 32.0%
- 9.0% 10Y total return vs EKSO's -99.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 36.0% revenue growth vs EKSO's -28.6% | |
| Quality / Margins | -10.8% margin vs EKSO's -135.7% | |
| Stability / Safety | Beta 0.92 vs IRBT's 5.21, lower leverage | |
| Dividends | 0.8% yield; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +79.3% vs IRBT's -97.7% | |
| Efficiency (ROA) | -3.0% ROA vs EKSO's -74.2%, ROIC -3.2% vs -88.1% |
EKSO vs IRBT vs CYBR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EKSO vs IRBT vs CYBR — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CYBR leads in 3 of 6 categories
IRBT leads 1 • EKSO leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CYBR leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CYBR is the larger business by revenue, generating $1.4B annually — 117.7x EKSO's $12M. CYBR is the more profitable business, keeping -10.8% of every revenue dollar as net income compared to EKSO's -135.7%. On growth, CYBR holds the edge at +18.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $12M | $547M | $1.4B |
| EBITDAEarnings before interest/tax | -$14M | -$151M | $23M |
| Net IncomeAfter-tax profit | -$16M | -$209M | -$147M |
| Free Cash FlowCash after capex | -$12M | -$107M | $259M |
| Gross MarginGross profit ÷ Revenue | +52.9% | +22.0% | +74.3% |
| Operating MarginEBIT ÷ Revenue | -134.1% | -29.5% | -7.7% |
| Net MarginNet income ÷ Revenue | -135.7% | -38.2% | -10.8% |
| FCF MarginFCF ÷ Revenue | -103.4% | -19.6% | +19.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -36.6% | -24.6% | +18.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -17.5% | -195.2% | +83.2% |
Valuation Metrics
IRBT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $29M | $2M | $20.6B |
| Enterprise ValueMkt cap + debt − cash | $30M | $95M | $21.2B |
| Trailing P/EPrice ÷ TTM EPS | -2.40x | -0.01x | -139.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 81.87x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 908.21x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 0.00x | 15.16x |
| Price / BookPrice ÷ Book value/share | 3.17x | 0.03x | 8.54x |
| Price / FCFMarket cap ÷ FCF | — | — | 79.60x |
Profitability & Efficiency
CYBR leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
CYBR delivers a -6.1% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-177 for EKSO. EKSO carries lower financial leverage with a 0.29x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRBT's 3.71x.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -177.4% | -112.9% | -6.1% |
| ROA (TTM)Return on assets | -74.2% | -43.3% | -3.0% |
| ROICReturn on invested capital | -88.1% | -38.6% | -3.2% |
| ROCEReturn on capital employed | -87.1% | -27.7% | -3.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.29x | 3.71x | 0.51x |
| Net DebtTotal debt minus cash | $1M | $93M | $599M |
| Cash & Equiv.Liquid assets | $1M | $134M | $623M |
| Total DebtShort + long-term debt | $3M | $227M | $1.2B |
| Interest CoverageEBIT ÷ Interest expense | -20.44x | -3.36x | — |
Total Returns (Dividends Reinvested)
CYBR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CYBR five years ago would be worth $34,006 today (with dividends reinvested), compared to $6 for IRBT. Over the past 12 months, EKSO leads with a +79.3% total return vs IRBT's -97.7%. The 3-year compound annual growth rate (CAGR) favors CYBR at 43.4% vs IRBT's -88.8% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +50.5% | -55.0% | -6.1% |
| 1-Year ReturnPast 12 months | +79.3% | -97.7% | +13.3% |
| 3-Year ReturnCumulative with dividends | -49.9% | -99.9% | +194.8% |
| 5-Year ReturnCumulative with dividends | -85.5% | -99.9% | +240.1% |
| 10-Year ReturnCumulative with dividends | -99.3% | -99.9% | +901.8% |
| CAGR (3Y)Annualised 3-year return | -20.6% | -88.8% | +43.4% |
Risk & Volatility
Evenly matched — EKSO and CYBR each lead in 1 of 2 comparable metrics.
Risk & Volatility
CYBR is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than IRBT's 5.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EKSO currently trades 87.4% from its 52-week high vs IRBT's 0.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 5.21x | 0.92x |
| 52-Week HighHighest price in past year | $13.50 | $6.10 | $526.19 |
| 52-Week LowLowest price in past year | $2.73 | $0.04 | $347.12 |
| % of 52W HighCurrent price vs 52-week peak | +87.4% | +0.9% | +77.7% |
| RSI (14)Momentum oscillator 0–100 | 59.9 | 33.9 | 38.9 |
| Avg Volume (50D)Average daily shares traded | 68K | 0 | 0 |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: EKSO as "Buy", CYBR as "Buy". Consensus price targets imply 12.3% upside for CYBR (target: $459) vs -49.2% for EKSO (target: $6). EKSO is the only dividend payer here at 0.79% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy |
| Price TargetConsensus 12-month target | $6.00 | — | $459.00 |
| # AnalystsCovering analysts | 4 | — | 49 |
| Dividend YieldAnnual dividend ÷ price | +0.8% | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — |
| Dividend / ShareAnnual DPS | $0.09 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.0% |
CYBR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IRBT leads in 1 (Valuation Metrics). 1 tied.
EKSO vs IRBT vs CYBR: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is EKSO or IRBT or CYBR a better buy right now?
For growth investors, CyberArk Software Ltd.
(CYBR) is the stronger pick with 36. 0% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EKSO or IRBT or CYBR?
Over the past 5 years, CyberArk Software Ltd.
(CYBR) delivered a total return of +240. 1%, compared to -99. 9% for iRobot Corporation (IRBT). Over 10 years, the gap is even starker: CYBR returned +901. 8% versus IRBT's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EKSO or IRBT or CYBR?
By beta (market sensitivity over 5 years), CyberArk Software Ltd.
(CYBR) is the lower-risk stock at 0. 92β versus iRobot Corporation's 5. 21β — meaning IRBT is approximately 468% more volatile than CYBR relative to the S&P 500. On balance sheet safety, Ekso Bionics Holdings, Inc. (EKSO) carries a lower debt/equity ratio of 29% versus 4% for iRobot Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — EKSO or IRBT or CYBR?
By revenue growth (latest reported year), CyberArk Software Ltd.
(CYBR) is pulling ahead at 36. 0% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: iRobot Corporation grew EPS 55. 3% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, CYBR leads at 32. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EKSO or IRBT or CYBR?
CyberArk Software Ltd.
(CYBR) is the more profitable company, earning -10. 8% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps -10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CYBR leads at -7. 7% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — CYBR leads at 74. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is EKSO or IRBT or CYBR more undervalued right now?
Analyst consensus price targets imply the most upside for CYBR: 12.
3% to $459. 00.
07Which pays a better dividend — EKSO or IRBT or CYBR?
In this comparison, EKSO (0.
8% yield) pays a dividend. IRBT, CYBR do not pay a meaningful dividend and should not be held primarily for income.
08Is EKSO or IRBT or CYBR better for a retirement portfolio?
For long-horizon retirement investors, CyberArk Software Ltd.
(CYBR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), +901. 8% 10Y return). iRobot Corporation (IRBT) carries a higher beta of 5. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CYBR: +901. 8%, IRBT: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between EKSO and IRBT and CYBR?
These companies operate in different sectors (EKSO (Healthcare) and IRBT (Consumer Cyclical) and CYBR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EKSO is a small-cap quality compounder stock; IRBT is a small-cap quality compounder stock; CYBR is a mid-cap high-growth stock. EKSO pays a dividend while IRBT, CYBR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.